Background: Cetuximab combined with chemoradiotherapy chemotherapy is the standard therapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, survival benefit is limited. The purpose of this study was to investigate the expression of epiregulin (EREG) and amphiregulin (AREG), as predictive prognostic markers for the efficacy of cetuximab combined with chemotherapy in R/M HNSCC. Methods: We conducted a retrospective analysis of 37 patients diagnosed with R/M HNSCC. Tumor samples were analyzed for EREG and AREG mRNA gene expression, and clinical outcomes evaluated. Results: Values of EREG and AREG were associated with significantly longer overall survival (OS) (P = .03 and P = .01, respectively), as well as progressionfree survival (PFS) (P = .04 and P = .04, respectively). Multivariate analysis revealed that AREG expression was significantly associated with OS and PFS. Conclusions: Patients with recurrent/metastatic HNSCC with higher EREG and AREG gene expression appear to benefit more from cetuximab combined with chemoradiotherapy chemotherapy than those with lower expression.
| INTRODUCTION
In the treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Vermorken et al reported in 2008 that the EXTREME regimen prolonged OS when given as first-line treatment for R/M HNSCC. 1 Although there is a worldwide effort to prolong survival for such patients, the regimen remains the standard for R/M HNSCC. 2 Predictive biomarkers for the efficacy of cetuximab regimens in head and neck cancer are thus needed to improve both the therapeutic index and cost-effectiveness, as well as to increase our understanding of resistance pathways to aid future drug development.
Epiregulin (EREG) and amphiregulin (AREG), ligands for the epidermal growth factor receptor (EGFR), have been suggested as putative biomarkers for the efficacy of cetuximab treatment, based on gene expression profiling in colon cancer. 3, 4 Jonker et al assessed the use of EREG expression as a prognostic biomarker for advanced colorectal cancer using tumor samples from a phase III clinical trial of cetuximab plus best supportive care versus best supportive care alone. 5 The report showed that in patients with pretreated
and KRAS wild-type colorectal cancer, high EREG expression was associated with a greater benefit from cetuximab therapy. Because KRAS is wild-type in more than 95% of patients with HNSCC, 6 we hypothesized that EREG and AREG expression may have a similar prognostic potential in HNSCC. The purpose of this study was thus to examine the correlation between ligand expression and clinical outcome in patients with R/M HNSCC treated with the combination of cetuximab and chemoradiotherapy.
| PATIENTS AND METHODS

| Study design and patient eligibility
The study was approved by the Institutional Review Board of Saitama Medical University International Medical Center (No. 16-238/2016). The study population consisted of patients who started cetuximab plus chemoradiotherapy for R/M disease with HNSCC at Saitama Medical University International Medical Center between January 2013 and October 2016. Patients who did not have a biopsy specimen or surgical specimen before treatment in our department were excluded. Also excluded was one patient who ceased cetuximab administration prematurely, because of a grade 4 infusion reaction in response to the cetuximab-containing regimen.
| Treatment regimen
Cetuximab was administered as an intravenous loading dose of 400 mg/m 2 for 120 minutes on day 1, followed by a maintenance schedule of 250 mg/m 2 intravenously for 60 minutes, once per week. The chemoradiotherapy regimen (which was combined with cetuximab) consisted of either paclitaxel 60 mg/m 2 intravenously over 60 minutes once per week; or cisplatin 80 mg/m 2 intravenously for 60 minutes, plus 5-fluorouracil (5-FU) 1000 mg/m 2 intravenously for 120 hours every 4 weeks for a total of 6 cycles, unless otherwise stopped for disease progression or intolerable toxicity. Selection for combined chemoradiotherapy was based on patient organ function (especially renal function), patient's desire, and platinum resistance (patients who were platinumrefractory). Patients who were platinum-refractory were defined as those with tumor progression or recurrence within 6 months of the last dose of platinum-containing chemotherapy or chemoradiotherapy. In patients who were platinumefractory cetuximab was administered in combination with paclitaxel. In certain cases, when toxicity related to cisplatin or 5-FU (in combination with cetuximab) occurred, therapy was changed to the cetuximab plus paclitaxel regimen. In cases with progressive disease (PD) on cetuximabcontaining regimens, or in those unable to continue because of side effects or the patient's desire, the regimen was changed to paclitaxel monotherapy, S-1 monotherapy, or best supportive care. Paclitaxel monotherapy (70 mg/m 2 intravenously) was administered over 60 minutes once per week. S-1 is a novel oral anticancer agent consisting of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate at a molar ratio of 1:0.4:1, respectively, based on the biochemical modulation of 5-fluorouracil. 
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C for 20 seconds, and 72 C for 1 second. The threshold cycle (CT) value for each gene was determined using the LightCycler480 SW 1.5.1 (Roche). The delta-CT (ΔCT) value, which is the difference between the CT value of the target gene and the CT value of the endogenous control gene, was also calculated using the same software, and was used for relative mRNA quantification.
| Statistical analysis
The most appropriate cutoff points for EREG and AREG expression were determined by receiver operating characteristic curve analysis. Correlations between ligand expression and patient characteristics were analyzed using the chisquare or the Fisher exact test for categorical variables. In survival analysis, three end points were assessed: OS, PFS, and PFS during the limited period of cetuximab administration. The OS was defined as the time from first administration of cetuximab until death from any cause. Progressionfree survival was defined as the time from first administration of cetuximab until the first objective observation of disease progression or death from any cause. The OS and PFS were calculated using Kaplan-Meier analysis, with differences assessed by log-rank test. We performed univariate analyses using the Cox proportional hazards regression model to identify prognostic factors associated with OS, PFS, and PFS during the limited period of cetuximab administration, which were then considered in a multivariate Cox proportional hazards regression analysis. All statistical analyses were performed with EZR. 9 All statistical tests were 2-sided, with p < .05 considered significant.
| RESULTS
| Patient characteristics
Of the 37 patients enrolled in this study, 29 (78.4%) were men and 8 (21.6%) were women, with a median age of 65 years (range 41-81 years). The follow-up period from the initial administration of cetuximab ranged from 1.7 months and 38.9 months, with a median of 7.2 months. Reasons for the administration of a cetuximab-containing regimen were as follows: 15 patients (40.5%) had locoregional recurrence, 20 patients (54.1%) had distant metastasis, and 2 patients (5.4%) had both locoregional recurrence and distant metastasis. Tumor subsites and patient characteristics are shown in Table 1 .
| The optimal cutoff value for EREG and AREG expression
Real-time polymerase chain reaction was carried out to estimate the expression of EREG and AREG. Using receiver operating characteristic curve analysis, we determined the optimal cutoff value of EREG and AREG for PD events during the limited period of administration of cetuximab. For these events, the area under the receiver operating characteristic curves for EREG was 0.62 with a 95% confidence interval (CI) of 0.43 to 0.80. In regard to AREG, the area under the curve was 0.50with a 95% CI of 0.30 to 0.70. A cutoff value for EREG of 15.87 presented a sensitivity of 69.2% and a specificity of 66.7% for PFS during the limited period of administration of cetuximab, and was associated with the strongest Youden index (Youden index = sensitivity + specificity -1). A cutoff value for AREG of 11.80 presented a sensitivity of 46.2% and a specificity of 62.5% for PFS during the limited period of administration of cetuximab and was also associated with the strongest Youden index. The cutoff values of 15.87 and 11.80 for EREG and AREG, respectively, were thus used for subsequent analysis.
| Comparative analysis of EREG/AREG expression and association with clinicopathologic characteristics in patients with R/M HNSCC
We defined EREG/AREG expression values above or below the indicated cutoff thresholds as representing high and low expression, respectively. High expression of EREG and AREG was found in 19 patients (51.4%) and 21 cases (56.8%), respectively. EREG expression was significantly correlated with AREG expression (Pearson product moment correlation coefficient, r = 0.73; p < .01; Figure 1 ). The clinicopathologic characteristics of patients were found to group according to their expression of EREG/AREG; however, EREG/AREG expression did not significantly correlate with clinicopathologic characteristics (Table 2) .
| Association between EREG/AREG expression and survival
We next performed Kaplan-Meier analysis to evaluate the ability of EREG/AREG to predict patient PFS and OS after treatment. In the overall cohort, Kaplan-Meier curves showed significantly better OS and PFS for patients with high tumor EREG expression compared with those with low EREG expression (p = .03 and p = .04, respectively; Figure 2 ), as well as significantly better OS and PFS for patients with high tumor AREG expression (p = .01, and p = .04, respectively, Figure 3 ). To clarify whether the relationship between the expression of AREG/EREG and survival differed between the 2 regimens used in this study, we also evaluated the OS and PFS associated with each regimen. In the cisplatin and 5-FU plus cetuximab regimen, KaplanMeier analysis showed significantly better OS for patients with high tumor AREG expression compared to those with low AREG expression (p = .047; Supporting Information Figure S1A ), and a significantly better PFS for patients with high tumor EREG expression (p = .045, Supporting InformationFigure S1B). In the paclitaxel plus cetuximab regimen, however, Kaplan-Meier analysis did not show any significant relationship between OS/PFS and AREG/AREG expression.
| Univariate and multivariate analysis
We calculated the impact of various factors and prognostic markers on survival on univariate as well as multivariate analysis in which covariate selection was performed using a backward elimination procedure. The results on univariate analysis demonstrated that EREG and AREG expression levels were significantly associated with OS (Table 3) . On multivariate analysis, AREG expression remained a significant determinant of OS (Table 3 ; p = .01). In the same way, we next assessed PFS on both univariate and multivariate analyses. Univariate analysis demonstrated that EREG and AREG expression were both significantly associated with PFS (Table 4) . On the multivariate analysis, AREG expression again remained a significant determinant of PFS (Table 4 ; p = 0.04). Finally, we assessed the relevance of these factors on PFS during the limited period of cetuximab administration, with univariate analysis demonstrating that rash acneiform had a significant impact on survival (Supporting Information Table S1 ). On multivariate analysis, however, there was no clinical factor that retained a significant effect on PFS during the limited period of cetuximab administration (Supporting Information Table S1 ).
| DISCUSSION
An association between EREG/AREG expression and the efficacy of cetuximab was initially reported in 2007 by Abbreviations: 5-FU, 5-fluorouracil; CR, complete response; L/R, local/ regional recurrence; PD, progressive disease; PR, partial response; SD, stable disease.
Khambata-Ford et al, 3 in a study of the tumor mRNA expression from 110 patients with advanced colorectal cancer, treated on a single-arm cetuximab monotherapy. Jonker et al also reported that in pretreated KRAS wild-type colorectal cancer, patients with high EREG gene expression appear to benefit more from cetuximab therapy than those with low expression. 5 The mechanism for this association is speculated to involve the stimulation of the EGFR by EREG and AREG through a positive feedback autocrine loop, with elevated expression of these ligands indicating potential dependence of the tumor on the EGFR pathway. 3 The EREG and AREG bind the same receptor, are known to be coregulated, and are genes found on same chromosome 4q13.3. 10 As such, it would be expected that they share similar predictive prognostic effects. Tepper et al reported that some EGFR ligands, including AREG, were highly expressed in 30% to 50% of HNSCC cell lines and that their expression was usually concurrent. 11 Jedlinski et al similarly showed that the EGFR ligand, like EREG and AREG, was expressed in a panel of 25 HNSCC cell lines. 12 In our study, we found that the expression of EREG and AREG was highly correlated ( Figure 1 ) and that high tumor expression of both ligands was associated with improved OS and PFS during cetuximab therapy (Figures 2 and 3) . Some investigators have reported factors that are significant predictors of outcome in patients with colorectal cancer receiving anti-EGFR therapy. Fujii et al reported that hypomagnesemia was associated with the overall response rate of anti-EGFR monoclonal antibody therapy in patients with metastatic colorectal cancer. 13 Kogawa et al also showed that early onset of skin toxicity and high skin toxicity grade are predictors of treatment efficacy and/or outcome in patients with advanced colorectal carcinoma treated with cetuximab. 14 Thus, on our univariate and multivariate analyses of survival with cetuximab-containing regimens, we included hypomagnesemia and rash acneiform as covariates. We found that AREG expression was a robust determinant of OS (Table 3 ; p = .01) and PFS (Table 4 ; p = .04). Subsequently, we focused on survival outcomes during the specific period in which cetuximab was administered. On univariate analysis, the PFS-Cmab was significantly longer in patients with rash acneiform grade G2 or G3 than in those with rash acneiform G1 or no rash acneiform, although this factor did not remain significant on multivariate analysis. This may mean that the presence of rash acneiform is correlated to cetuximab treatment response, but not to survival. Jedlinski et al evaluated the expression of EREG and AREG in 25 head and neck cancer cell lines, showing that cisplatin-resistant cell lines had lower expression of AREG than sensitive cell lines. Similarly, cetuximabresistant cell lines tended to have lower expression of FIGURE 2 Kaplan-Meier estimates of A, overall survival and B, progression-free survival of patients with recurrent/metastatic disease treated with cetuximab-containing regimen according to EREG expression. Overall survival and progression-free survival was significantly better in patients with EREG high than those with EREG low (p = .03, P = .04, respectively). p Values were calculated by the log-rank test FIGURE 3 Kaplan-Meier estimates of A, overall survival and B, progression-free survival of patients with recurrent/metastatic disease treated with cetuximab-containing regimen according to AREG expression. Overall survival and was progression-free survival significantly better in patients with AREG high than those with AREG low (P = .01, P = .04, respectively). p Values were calculated by the log-rank test EREG than sensitive cell lines. 12 Consistent with this, the expression of AREG/EREG in our study only showed a significant correlation with survival in patients receiving a cisplatin-containing regimen. In R/M HNSCC, cetuximab combined with chemoradiotherapy is usually administered as first-line treatment. In our study, all patients received combined cetuximab chemoradiotherapy until the occurrence of nontolerable toxicity, or the completion of more than 6 cycles of cisplatin and 5FU. The EREG and AREG may thus be relevant as biomarkers not only for the efficacy of cetuximab, but also for the combined chemoradiotherapy regimen used in patients with R/M HNSCC. Consistently, our results showed that AREG expression was significantly associated with better OS and PFS. We speculate that the reason EREG expression did not remain a significant determinant of OS and PFS is that the expression of AREG and EREG is highly correlated, and the factors may thus be confounded.
To our knowledge, this study is the first to evaluate the association between the tumor expression of EREG/ AREG and prognosis after cetuximab-containing therapy in R/M HNSCC formally. However, there are some limitations of the present study that should be considered. First, the data were collected retrospectively. Second, the relatively small number of participants means that the statistical power of the analysis is limited, and additional studies with larger cohorts are therefore required. Third, we used tissue specimens before first treatment, and the gene expression profile of the tumors may thus change over time and/or in response to radiotherapy or chemoradiotherapy.
A previous study evaluated EREG and AREG protein expression in the tumors and serum samples of 73 patients with colorectal cancer. 15 Using immunohistochemical and enzyme-linked immunosorbent assay, they reported 90% coexpression of these ligands and concluded that high ligand expression is a poor prognostic factor for this cancer. We are thus planning a study to evaluate the association of EREG/ AREG expression with serum and tumors from patients with R/M HNSCC, with the purpose of validating the use of EREG/AREG as blood biomarkers to predict the effectiveness of cetuximab-based regimens before treatment. We believe that future improvements in cancer outcomes, and the minimization of patient exposure to ineffective therapies, will require a shift in oncology culture toward tumor profiling at diagnosis, with treatments based on molecular signatures. Abbreviation: CI, confidence interval.
| CONCLUSION
Our study suggests that EREG and AREG expression in tumor tissues may be used as prognostic biomarkers for patients with R/M HNSCC, a finding that is consistent with previous reports in the colorectal cancer field. Further studies are warranted to validate the predictive value of EREG and AREG as biomarkers in a larger cohort of patients with R/M HNSCC. Abbreviation: CI, confidence interval.
